<img alt="" src="https://secure.agile-company-365.com/781893.png" style="display:none;">

Trajan Unveils Plan for Microsampling Across Research, Healthcare

Combining artificial intelligence (AI) with other medical diagnostic technologies and remote blood microsampling devices is a winning recipe for continued global health innovation in the near future, predicts Stephen Tomisich, the CEO of Trajan Scientific and Medical, a global biomedical-biotechnology company headquartered in Melbourne, Australia.

According to an article titled "A Natural Fit for Two Top Players" by Helen Trinca that appeared in the January 7, 2023, issue of The Weekend Australian, Tomisich shared that the vision for Trajan is to collaborate with innovators in science, medicine and technology to facilitate the decentralization of health care and preventive medicine. This vision includes finding ways to take health monitoring out of facilities and into the field to improve access and benefits for more people.

In his interview with Trinca for the article, Tomisich stated, "A few years back we started asking ourselves, what are the tools, what’s the science that’s going to make [decentralized healthcare] possible? We came to the conclusion that sampling blood outside of the clinical setting was essential.”Business News Australia, Stephen Tomisich, Trajan

Trajan Fosters Research Collaborations That Can Leverage Microsampling & Advance Healthcare

Trinca reports that in 2020, Trajan began a collaboration with Australia's Baker Heart and Diabetes Institute, where researchers were using chemistry and tools such as mass spectrometry to develop new technology for assessing risk based on lipidomics. Under the leadership of Peter Meikle, head of the Baker's systems biology area, they studied cellular lipids and developed cutting-edge tests for heart disease and diabetes using a single drop of blood.

The Institute had the scientific capability to develop the tests but needed to figure out how to translate their tests for real-world healthcare applications. They needed a microsampling device that could be offered in easy-to-use sampling test kits that healthcare providers could ship to people at home for remote sampling.

hemaPEN device from TrajanThat is where Trajan stepped in to offer the company's expertise and products in automation, analytical measurements and remote microsampling technology. Tomisich worked with Meikle to further develop the Institute's risk assessment test for a range of cardiovascular and metabolic diseases.

The project moved forward using Trajan's hemaPEN™ microsampling device. Marketed by Neoteryx, Trajan's microsampling product brand, this portable device can simultaneously collect and store 4 homogenous blood samples from a drop of blood collected from a single finger-stick. The test will be made possible with the microsamples collected remotely using the hemaPEN.

Can remote microsampling improve access and management of cardiovascular disease?

The article explains that the goal of the collaboration is to commercialize this lipids test for use by more people, particularly those living in remote areas who can't easily travel to hospitals or pathology labs in city centers. Once the test is available, clinicians will be able to use the information to better manage their patients' health.

Traditional testing for cardiovascular conditions involves lab tests to measure cholesterol and triglycerides in blood samples as risk markers for heart and other metabolic diseases. The new test from the Institute can measure more than 200 lipids, providing a more powerful tool and "a snapshot of a patient’s metabolism to allow more accurate stratification of risk levels." The analysis of the blood samples is done via algorithms developed by machine learning or artificial intelligence (AI).

Meikle added that the test is "potentially transformative, especially for patients who doctors find hard to identify and treat – those who are not high risk, are at no risk, but who sit in the mid-range for likely development of cardiometabolic conditions."

In response to Trinca's question about how this new test from just "a drop of blood" compares to other blood tests fraudulently marketed by the failed blood-testing company Theranos, Meikle said, "As scientists we need to be careful about not overpromising and underdelivering. Over the last 10 years or more we have been building up the evidence and having this published in scientific journals, so we’re not just spinning hype. We have analyzed probably 50,000 blood samples and these models have been developed on 10,000 individuals, and we validate those models on separate cohorts.”

Trajan, which is ranked number two on the list of companies collaborating with Australian universities, also is committed to following the appropriate scientific protocols before bringing new technologies to market. In stark contrast to Theranos, Trajan prioritizes safety and transparency in all endeavors and research partnerships, particularly those aimed at helping the company fulfill its goal of providing scientific tools and solutions that enrich personal health.

"We say to partners like the Baker, just focus on what you are best at, which is continuing to develop this model and let us focus on what we’re best at. And then you put the two together," said Tomisich.

This is curated content. To read more about the collaboration between Trajan and The Baker Institute, read the original article in The Weekend Australian or on the Trajan blog.

New call-to-action

In some territories our devices are supplied for therapeutic or IVD use Outside of those territories our devices are supplied for research use only


No Comments Yet

Let us know what you think

Receive Blog Notifications